BRPI0606278A2 - aminas de 1,3-diidro-benzimidazol-2-ilideno como inbidores de replicação de vìrus sincicial respiratório - Google Patents
aminas de 1,3-diidro-benzimidazol-2-ilideno como inbidores de replicação de vìrus sincicial respiratórioInfo
- Publication number
- BRPI0606278A2 BRPI0606278A2 BRPI0606278-4A BRPI0606278A BRPI0606278A2 BR PI0606278 A2 BRPI0606278 A2 BR PI0606278A2 BR PI0606278 A BRPI0606278 A BR PI0606278A BR PI0606278 A2 BRPI0606278 A2 BR PI0606278A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen
- alkyl
- substituted
- benzimidazol
- dihydro
- Prior art date
Links
- -1 1,3-dihydro-benzimidazol-2-ylidene amines Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000029812 viral genome replication Effects 0.000 title abstract 2
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000000160 oxazolidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000001984 thiazolidinyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102127 | 2005-03-17 | ||
| EP05102127.7 | 2005-03-17 | ||
| PCT/EP2006/060852 WO2006097534A1 (en) | 2005-03-17 | 2006-03-17 | 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0606278A2 true BRPI0606278A2 (pt) | 2009-06-09 |
| BRPI0606278B1 BRPI0606278B1 (pt) | 2020-09-08 |
| BRPI0606278B8 BRPI0606278B8 (pt) | 2021-05-25 |
Family
ID=34939009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606278A BRPI0606278B8 (pt) | 2005-03-17 | 2006-03-17 | aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7956196B2 (pt) |
| EP (1) | EP1951704B1 (pt) |
| JP (1) | JP5289934B2 (pt) |
| CN (1) | CN101142208B (pt) |
| AU (1) | AU2006224533B9 (pt) |
| BR (1) | BRPI0606278B8 (pt) |
| CA (1) | CA2600507C (pt) |
| ES (1) | ES2574670T3 (pt) |
| MX (1) | MX2007011292A (pt) |
| RU (1) | RU2410382C2 (pt) |
| WO (1) | WO2006097534A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084728A2 (en) * | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| US8759520B2 (en) * | 2008-12-08 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
| EP3512840B1 (en) * | 2016-09-14 | 2024-03-06 | Yufeng Jane Tseng | Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| BR112022000653A2 (pt) * | 2019-07-19 | 2022-03-03 | Abivax | Composto de formula (i), composição farmacêutica e processo de síntese para a fabricação de novos compostos de fórmula (i) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE31812B1 (en) * | 1967-02-03 | 1973-01-10 | Merck & Co Inc | Benzimidazole derivatives |
| JPS4842875B1 (pt) * | 1969-01-29 | 1973-12-14 | ||
| US4179505A (en) * | 1977-03-30 | 1979-12-18 | Janssen Pharmaceutica N.V. | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
| IL147327A0 (en) | 1999-06-28 | 2002-08-14 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
| ES2215670T3 (es) * | 1999-06-28 | 2004-10-16 | Janssen Pharmaceutica N.V. | Inhibidores de la replicacion del virus sincitial respiratorio. |
| SI1196408T1 (en) * | 1999-06-28 | 2005-02-28 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
-
2006
- 2006-03-17 MX MX2007011292A patent/MX2007011292A/es active IP Right Grant
- 2006-03-17 AU AU2006224533A patent/AU2006224533B9/en not_active Ceased
- 2006-03-17 RU RU2007138380/04A patent/RU2410382C2/ru active IP Right Revival
- 2006-03-17 JP JP2008501332A patent/JP5289934B2/ja not_active Expired - Fee Related
- 2006-03-17 ES ES06708798.1T patent/ES2574670T3/es not_active Expired - Lifetime
- 2006-03-17 EP EP06708798.1A patent/EP1951704B1/en not_active Expired - Lifetime
- 2006-03-17 CN CN2006800085588A patent/CN101142208B/zh not_active Expired - Fee Related
- 2006-03-17 US US11/908,538 patent/US7956196B2/en active Active
- 2006-03-17 WO PCT/EP2006/060852 patent/WO2006097534A1/en not_active Ceased
- 2006-03-17 CA CA2600507A patent/CA2600507C/en not_active Expired - Lifetime
- 2006-03-17 BR BRPI0606278A patent/BRPI0606278B8/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008533103A (ja) | 2008-08-21 |
| AU2006224533B9 (en) | 2012-06-21 |
| EP1951704B1 (en) | 2016-03-16 |
| CA2600507A1 (en) | 2006-09-21 |
| JP5289934B2 (ja) | 2013-09-11 |
| CN101142208A (zh) | 2008-03-12 |
| CA2600507C (en) | 2013-10-22 |
| CN101142208B (zh) | 2012-05-23 |
| MX2007011292A (es) | 2007-11-07 |
| WO2006097534A1 (en) | 2006-09-21 |
| BRPI0606278B8 (pt) | 2021-05-25 |
| US20080146564A1 (en) | 2008-06-19 |
| RU2410382C2 (ru) | 2011-01-27 |
| ES2574670T3 (es) | 2016-06-21 |
| AU2006224533B2 (en) | 2012-05-03 |
| US7956196B2 (en) | 2011-06-07 |
| AU2006224533A1 (en) | 2006-09-21 |
| EP1951704A1 (en) | 2008-08-06 |
| BRPI0606278B1 (pt) | 2020-09-08 |
| RU2007138380A (ru) | 2009-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507065B8 (pt) | derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos | |
| CY1108142T1 (el) | Βενζιμιδαζολες που περιεχουν μορφολινυλ ως αναστολεις της αντιγραφης του συγκυτιακου ιου του αναπνευστικου | |
| JOP20210301A1 (ar) | بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1 | |
| BRPI0308495B8 (pt) | composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto | |
| PL378064A1 (pl) | Pirymidyny i triazyny hamujące replikację wirusa HIV | |
| BRPI0606524A2 (pt) | derivados de indol para o tratamento de infecções virais | |
| BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
| BR0309522A (pt) | Compostos piridina ou sais destes e herbicidas contendo os mesmos | |
| BRPI0913457A2 (pt) | "composto, composição farmacêutica, e, uso do composto" | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| BRPI0515081B8 (pt) | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida | |
| BR112012014164A2 (pt) | inibidores da esfingosina quinase | |
| NO20084186L (no) | Nye aminer | |
| BR112012014884A2 (pt) | inibidores de esfingosina quinase | |
| NO20050088L (no) | Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav | |
| BRPI0900983A2 (pt) | compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos | |
| BRPI0414436A (pt) | processo para a preparação de derivados de 2-oxo-1-pirrolidina e seus sais | |
| BR0115210A (pt) | Derivado de pirimidina e produto herbicida contendo o mesmo | |
| BRPI0511722A (pt) | 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina | |
| BRPI0606278A2 (pt) | aminas de 1,3-diidro-benzimidazol-2-ilideno como inbidores de replicação de vìrus sincicial respiratório | |
| HRP20050775A2 (en) | Quinolinone/benzoxazinone derivatives and uses thereof | |
| UY30048A1 (es) | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
| BRPI0507499A (pt) | composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5 | |
| BRPI0714211B8 (pt) | derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2766 DE 09-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |